The role of acute care surgery in the treatment of severe, complicated Clostridium difficile-associated disease

Journal of Trauma and Acute Care Surgery

Volumn 73, Issue 4, 2012, Pages 789-800

  Carchman, Evie H ^a   Peitzman, Andrew B ^a   Simmons, Richard L ^a   Zuckerbraun, Brian S ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACITRACIN; COLESTYRAMINE; FIDAXOMICIN; FUSIDIC ACID; METRONIDAZOLE; NITAZOXANIDE; PROBIOTIC AGENT; RIFAXIMIN; TEICOPLANIN; TIGECYCLINE; TOLEVAMER; VANCOMYCIN;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; AGE DISTRIBUTION; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; CONSULTATION; DISEASE ASSOCIATION; DISEASE SEVERITY; EMERGENCY CARE; HUMAN; ILEUS; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; LONG TERM CARE; MENTAL HEALTH; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK FACTOR; TREATMENT RESPONSE;

ACUTE DISEASE; CLOSTRIDIUM DIFFICILE; COLECTOMY; COLITIS; COLON; CRITICAL CARE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS;

EID: 84866972891     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0b013e318265d19f     Document Type: Article

References (75)

1. Gravel D, MillerM, Simor A, Taylor G, GardamM, McGeer A, Hutchinson J, Moore D, Kelly S, Boyd D, et al. Health careYassociated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis. 2009;48:568-576.
2. US Department of Health and Human Services. HCUPnet 2010. Available at http://hcupnet.ahrq.gov. Accessed March 2012.
3. SongX, Bartlett JG, SpeckK, NaegeliA, CarrollK, Perl TM.Rising economic impact of Clostridium difficileYassociated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol. 2008;29:823-828.
4. Gould CV, McDonald LC. Bench-to-bedside review: Clostridium difficile colitis. Crit Care. 2008;12:203.
5. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficileYrelated hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis. 2008;14:929-931. (Pubitemid 351838602)
6. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34:346-353. (Pubitemid 34062235)
7. Drudy D, Calabi E, Kyne L, Sougioultzis S, Kelly E, Fairweather N, Kelly CP. Human antibody response to surface layer proteins in Clostridium difficile infection. FEMS Immunol Med Microbiol. 2004;41:237-242. (Pubitemid 38757871)
8. Katchar K, Taylor CP, Tummala S, Chen X, Sheikh J, Kelly CP. Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficileYassociated disease. Clin Gastroenterol Hepatol. 2007;5:707-713. (Pubitemid 46830983)
9. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD Jr, Leney M, Sloan S, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362:197-205.
10. Dawson AE, Shumak SL, Redelmeier DA. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010; 362:1445; author reply 1445-1446.
11. Cloud J, Kelly CP. Update on Clostridium difficile associated disease. Curr Opin Gastroenterol. 2007;23:4-9. (Pubitemid 44875902)
12. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med. 2002;346:334-339.
13. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl 1):S12-S18. (Pubitemid 351323661)
14. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficileYassociated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353: 2442-2449. (Pubitemid 41770165)
15. Garey KW, Dao-Tran TK, Jiang ZD, Price MP, Gentry LO, Dupont HL. A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics. J Hosp Infect. 2008;70: 142-147.
16. Deshpande A, Pant C, Jain A, Fraser TG, Rolston DD. Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence. Curr Med Res Opin. 2008;24:329-333. (Pubitemid 351294381)
17. Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficileYassociated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254-1260. (Pubitemid 41532667)
18. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, Johnson S, Gerding DN. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433-2441. (Pubitemid 41770164)
19. Privitera G, Scarpellini P, Ortisi G, Nicastro G, Nicolin R, de Lalla F. Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. Antimicrob Agents Chemother. 1991;35:208-210.
20. Carignan A, Allard C, Pepin J, Cossette B, Nault V, Valiquette L. Risk of Clostridium difficile infection after perioperative antibacterial prophylaxis before and during an outbreak of infection due to a hypervirulent strain. Clin Infect Dis. 2008;46:1838-1843.
21. Ricciardi R, Rothenberger DA, Madoff RD, Baxter NN. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg. 2007;142:624-631; discussion 631. (Pubitemid 47080440)
22. Leclair MA, Allard C, Lesur O, Pepin J. Clostridium difficile infection in the intensive care unit. J Intensive Care Med. 2010;25:23-30.
23. Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, Simmons RL. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002;235:363-372. (Pubitemid 34183887)
24. Byrn JC, Maun DC, Gingold DS, Baril DT, Ozao JJ, Divino CM. Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. Arch Surg. 2008;143:150-154; discussion 155. (Pubitemid 351281618)
25. Aronsson B, Granstrom M, Mollby R, Nord CE. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection. 1985;13:97-101. (Pubitemid 15030800)
26. Leung DY, Kelly CP, Boguniewicz M, Pothoulakis C, LaMont JT, Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr. 1991;118 (4 Pt 1):633-637.
27. Warny M, Vaerman JP, Avesani V, Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun. 1994;62:384-389. (Pubitemid 24033753)
28. Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, Toye B, Beaudoin A, Frost EH, Gilca R, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365:1693-1703.
29. Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, Talmor D. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170:784-790.
30. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102:2047-2056; quiz 2057. (Pubitemid 47301504)
31. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr. Clostridium difficileYassociated diarrhea and colitis. Infect Control Hosp Epidemiol. 1995;16:459-477.
32. Wren MW, Kinson R, Sivapalan M, Shemko M, Shetty NR. Detection of Clostridium difficile infection: a suggested laboratory diagnostic algorithm. Br J Biomed Sci. 2009;66:175-179.
33. Novak-Weekley SM, Marlowe EM, Miller JM, Cumpio J, Nomura JH, Vance PH, Weissfeld A. Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms. J Clin Microbiol. 2010;48: 889-893.
34. Kirkpatrick ID, Greenberg HM. Evaluating the CT diagnosis of Clostridium difficile colitis: should CT guide therapy? AJR Am J Roentgenol. 2001;176:635-639. (Pubitemid 32181955)
35. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431-455.
36. Bartlett JG. New antimicrobial agents for patients with Clostridium difficile infections. Curr Infect Dis Rep. 2009;11:21-28.
37. Bartlett JG. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin Infect Dis. 2008;46:1489-1492. (Pubitemid 351706727)
38. Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, GraningerW. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficileYassociated diarrhea. Clin Infect Dis. 1996;22:813-818. (Pubitemid 26255600)
39. Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, Lee JT Jr. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficileYassociated diarrhoea and colitis. Lancet. 1983;2:1043-1046. (Pubitemid 14235361)
40. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficileY associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007; 45:302-307. (Pubitemid 47101025)
41. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422-431.
42. Shetler K, Nieuwenhuis R, Wren SM, Triadafilopoulos G. Decompressive colonoscopy with intracolonic vancomycin administration for the treatment of severe pseudomembranous colitis. Surg Endosc. 2001;15:653-659. (Pubitemid 32622608)
43. Haaga JR, Bick RJ, Zollinger RM Jr. CT-guided percutaneous catheter cecostomy. Gastrointest Radiol. 1987;12:166-168. (Pubitemid 17043722)
44. Kyne L, Kelly CP. Recurrent Clostridium difficile diarrhoea. Gut. 2001;49:152-153. (Pubitemid 32601893)
45. Bergamin B, Hess T, Jost R, Ballmer PE, Imoberdorf R. Recurrent Clostridium difficile enterocolitis [in German]. Schweiz Med Wochenschr. 2000;130:1681-1684.
46. Venuto C, Butler M, Ashley ED, Brown J. Alternative therapies for Clostridium difficile infections. Pharmacotherapy. 2010;30:1266-1278.
47. Brandt LJ, Borody TJ, Campbell J. Endoscopic fecal microbiota transplantation: "first-line" treatment for severe Clostridium difficile infection? J Clin Gastroenterol. 2011;45:655-657.
48. McFarland LV. Emerging therapies for Clostridium difficile infections. Expert Opin Emerg Drugs. 2011;16:425-439.
49. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010;16:2202-2222.
50. Segarra-Newnham M. Probiotics for Clostridium difficileYassociated diarrhea: focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii. Ann Pharmacother. 2007;41:1212-1221. (Pubitemid 47122558)
51. Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C, Giannasca PJ, Lee CK, Warny M, Monath TP, et al. Clostridium difficile toxoid vaccine in recurrent C. difficileYassociated diarrhea. Gastroenterology. 2005;128:764-770.
52. Salcedo J, Keates S, Pothoulakis C, Warny M, Castagliuolo I, LaMont JT, Kelly CP. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut. 1997;41:366-370. (Pubitemid 27428197)
53. Markelov A, Livert D, Kohli H. Predictors of fatal outcome after colectomy for fulminant Clostridium difficile colitis: a 10-year experience. dr. markelov@gmail.com. Am Surg. 2011;77:977-980.
54. Ali SO, Welch JP, Dring RJ. Early surgical intervention for fulminant pseudomembranous colitis. Am Surg. 2008;74:20-26. (Pubitemid 351396878)
55. Sailhamer EA, Carson K, Chang Y, Zacharias N, Spaniolas K, Tabbara M, Alam HB, DeMoya MA, Velmahos GC. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg. 2009;144: 433-439; discussion 439-440.
56. Butala P, Divino CM. Surgical aspects of fulminant Clostridium difficile colitis. Am J Surg. 2010;200:131-135.
57. Lamontagne F, Labbe AC, Haeck O, Lesur O, Lalancette M, Patino C, Leblanc M, Laverdiere M, Pepin J. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg. 2007;245:267-272. (Pubitemid 46148486)
58. Koss K, Clark MA, Sanders DS, Morton D, Keighley MR, Goh J. The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis. 2006;8:149-154. (Pubitemid 43372465)
59. Medich DS, Lee KK, Simmons RL, Grubbs PE, Yang HC, Showalter DP. Laparotomy for fulminant pseudomembranous colitis. Arch Surg. 1992;127: 847-852; discussion 852-843.
60. Longo WE, Mazuski JE, Virgo KS, Lee P, Bahadursingh AN, Johnson FE. Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum. 2004;47:1620-1626. (Pubitemid 39331972)
61. Dudukgian H, Sie E, Gonzalez-Ruiz C, EtzioniDA, Kaiser AM. C. difficile colitisVpredictors of fatal outcome. J Gastrointest Surg. 2010;14:315-322.
62. Gujja D, Friedenberg FK. Predictors of serious complications due to Clostridium difficile infection. Aliment Pharmacol Ther. 2009;29:635-642.
63. Belmares J, Gerding DN, Tillotson G, Johnson S. Measuring the severity of Clostridium difficile infection: implications for management and drug development. Expert Rev Anti Infect Ther. 2008;6:897-908.
64. McEllistrem MC, Carman RJ, Gerding DN, Genheimer CW, Zheng L. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis. 2005;40:265-272. (Pubitemid 40110672)
65. Jaber MR, Olafsson S, Fung WL, Reeves ME. Clinical review of the management of fulminant Clostridium difficile infection. Am J Gastroenterol. 2008;103:3195-3203; quiz 3204.
66. Hall J, Horsley M. Diagnosis and management of patients with Clostridium difficileYassociated diarrhoea. Nurs Stand. 2007;21:49-56; quiz 58.
67. Greenstein AJ, Byrn JC, Zhang LP, Swedish KA, Jahn AE, Divino CM. Risk factors for the development of fulminant Clostridium difficile colitis. Surgery. 2008;143:623-629.
68. Pepin J, Vo TT, Boutros M, Marcotte E, Dial S, Dube S, Vasilevsky CA, McFadden N, Patino C, Labbe AC. Risk factors for mortality following emergency colectomy for fulminant Clostridium difficile infection. Dis Colon Rectum. 2009;52:400-405.
69. Perera AD, Akbari RP, Cowher MS, Read TE, McCormick JT, Medich DS, Celebrezze JP, Jr, Beck SJ, Fischer PE, Caushaj PF. Colectomy for fulminant Clostridium difficile colitis: predictors of mortality. Am Surg. 2010;76:418-421.
70. Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg. 2011;254:423-427; discussion 427-429.
71. Olivas AD, Umanskiy K, Zuckerbraun B, Alverdy JC. Avoiding colectomy during surgical management of fulminant Clostridium difficile colitis. Surg Infect (Larchmt). 2010;11:299-305.
72. Saylor JL, Anderson CB, Tedesco FJ. Pseudomembranous colitis treated with completely diverting ileostomy. Arch Surg. 1976;111:596-598. (Pubitemid 8002425)
73. Turnbull RB Jr, Fazio V. Advances in the surgical technique of ulcerative colitis surgery: endoanal proctectomy and two-directional myotomy ileostomy. Surg Annu. 1975;7:315-329.
74. Oppermann TE, Christopherson WA, Stahlfeld KR. Fulminant Clostridium difficile colitis isolated to the ascending colon by a diverting transverse loop colostomy. Am Surg. 2009;75:859-860.
75. Liacouras CA, Piccoli DA. Whole-bowel irrigation as an adjunct to the treatment of chronic, relapsing Clostridium difficile colitis. J Clin Gastroenterol. 1996;22:186-189. (Pubitemid 26118621)